The Hepatovirus Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Hepatovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hepatovirus Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hepatovirus Infections and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Hepatovirus Infections by ten companies/universities/institutes. The top development phase for Hepatovirus Infections is preclinical with four drugs in that stage. The Hepatovirus Infections pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hepatovirus Infections pipeline products market are: Indian Immunologicals, Liaoning Cheng Da Biotechnology and Suzhou Ribo Life Sciences.
The key targets in the Hepatovirus Infections pipeline products market include Terminal Nucleotidyltransferase 4A (Non Canonical Poly(A) RNA Polymerase PAPD7 or PAP Associated Domain Containing Protein 7 or TENT4A or EC 2.7.7.19), and Terminal Nucleotidyltransferase 4B (Non canonical Poly(A) RNA Polymerase PAPD5 or PAP-Associated Domain Containing Protein 5 or Terminal Guanylyltransferase or PAPD5 or TENT4B or EC 2.7.7.19).
The key mechanisms of action in the Hepatovirus Infections pipeline product include Terminal Nucleotidyltransferase 4B (Non canonical Poly(A) RNA Polymerase PAPD5 or PAP-Associated Domain Containing Protein 5 or Terminal Guanylyltransferase or PAPD5 or TENT4B or EC 2.7.7.19) Inhibitor with one drug in Preclinical. The Hepatovirus Infections pipeline products include two routes of administration with the top ROA being Intramuscular and five key molecule types in the Hepatovirus Infections pipeline products market including Inactivated Vaccine, and Small Molecule.
Hepatovirus Infections overview
Virus that affecting the functionality of liver (hepatic) known as hepatovirus resulting in hepatitis. These are classified into five different types of hepatitis A, hepatitis B, Hepatitis D, Hepatitis C and hepatitis E. Of all these hepatitis A falls under the genus hepatovirus and it is the small, unenveloped RNA virus and is the only species that affects humans. HAV that belongs to picornavirus family results in hepatitis and is most observed in children. Mode of infection is fecal-oral route. Jaundice is the common seen symptom, and its incubation period is four weeks. HAV enters the body through contaminated food, water or other ways and spreads through blood and targets liver where viral replication occurs. Diagnosed by anti-HAV immunoglobulin IgM. No treatment is required for HAV as it is self-limited but for further prevention HAV vaccines are prescribed.
For a complete picture of Hepatovirus Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
